Processa Pharmaceuticals held annual shareholder meeting, quorum met by proxy or in person
PCSA•Annual shareholder meeting results
Processa Pharmaceuticals held its 2026 annual shareholder meeting on July 30, 2026.
Shareholders backed an amended 2019 omnibus incentive plan, authorizing an additional 200,000 shares for issuance under the plan.
Shareholders ratified Cherry Bekaert as independent registered public accounting firm for the fiscal year ending Dec. 31, 2026.
Shareholders approved the slate of six directors to serve until the next annual meeting.
